ArticleClinical and experimental pediatrics2026
Validation of a new Japanese classification for predicting severe bronchopulmonary dysplasia in preterm infants.
Article in Clinical and experimental pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early prediction of bronchopulmonary dysplasia using new classification in high-risk preterm infants.Clinical and experimental pediatrics · 2026Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchopulmonary dysplasia (BPD) is the most prevalent chronic lung disease in very preterm infants; however, conventional classifications have limited ability to predict severity before 36 weeks' postmenstrual age (PMA). A new Japanese classification, based on small for gestational age (SGA), bubbly/cystic chest radiographic findings, and chorioamnionitis (CAM), was proposed to enable earlier risk stratification. However, its validation in homogeneous cohorts is warranted. PURPOSE: This study aimed to examine the association between this new Japanese classification and severe BPD development at 36 weeks' PMA in a secondary analysis of a randomized controlled trial (RCT).
methodsA retrospective secondary analysis of a multicenter, double-blind RCT of inhaled corticosteroids in 12 tertiary neonatal intensive care units in Japan (2006-2009) was performed. Infants with a birth weight (BW)<1,000 g and requiring mechanical ventilation were enrolled. Of those 211 infants, 194 survivors were analyzed. Severe BPD was defined by National Institute of Child Health and Human Development criteria as requiring supplemental oxygen (fraction of inspired O2 >0.30) or positive pressure ventilation at 36 weeks' PMA. Logistic regression analyses were adjusted for gestational age, BW, sex, Apgar score, maternal steroid use, respiratory distress syndrome, and patent ductus arteriosus.
resultsAmong the 194 infants, 25 were SGA, 45 had bubbly/cystic findings, and 86 had CAM. Severe BPD occurred in 80 infants. A multivariate analysis identified SGA (adjusted odds ratio [aOR], 3.32; 95% confidence interval [CI], 1.16-9.48; P=0.032) and bubbly/cystic findings (aOR, 10.88; 95% CI, 4.43-26.72; P<0.01) as independent risk factors. Compared with type II (non-CAM, no bubbly/cystic findings), type I (bubbly/cystic only: aOR, 6.21; 95% CI, 1.93-14.36) and type III (CAM plus bubbly/cystic: aOR, 15.32; 95% CI, 2.48-46.32) were significantly associated with severe BPD.
conclusionThe new Japanese classification demonstrated that SGA and bubbly/cystic findings at day 28 independently predicted severe BPD. Early stratification using this classification may facilitate the early identification of high-risk infants for targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.